http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102013023768-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4326bdf7bf020ccfc5f86faa5bbd01f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecaa35143dd955d729ebd927025e6263 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-90 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-008 |
| filingDate | 2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c5b3583374aa72f0bd74a07204ef3a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a15de41fa9f63114f7938a4969f407d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a52034417f85070ee5242ed0e356250 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da88a9f81f8d214d26f3f21872e3f91c |
| publicationDate | 2016-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102013023768-A2 |
| titleOfInvention | therapeutic vaccine in human and / or canine visceral leishmaniasis immunotherapy |
| abstract | Therapeutic vaccine for human and / or canine visceral leishmaniasis immunotherapy due to the increase in cases of visceral leishmaniasis (lv) and its severity in Brazil, the search for new treatment strategies is necessary. In this context, the present invention has developed a therapeutic vaccine composed of l antigens. braziliensis associated with adjuvant monophosphoryl lipid a (mpl), this vaccine being used as a strategy against lv (human and / or canine). dogs naturally infected by l. infantum and presenting clinical signs and symptoms of canine visceral leishmaniasis (lvc) were treated with 3 sets of 10 vaccine doses. The main results were the restoration of hematological and biochemical parameters and improvement of the immune status. In addition, dogs showed increased lymphocyte proliferation and cd4 + and t cd8 + cells, with increased ifn-y production in cd4 + and t cd8 + cells and reduction in il-4 production. The gradual improvement of clinical signs / symptoms during treatment has been observed since the first series of immunotherapy, and became more evident by the end of the third series. These results demonstrate the important effect of immunotherapy using the lbmpl vaccine on active lvc and indicated that this therapeutic vaccine promotes effective action in the regression of clinical signs and symptoms of lv. |
| priorityDate | 2013-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 133.